How long does it take to take Palbociclib for breast cancer

For patients with HR-positive, HER2-negative advanced or metastatic breast cancer, oral palbociclib (palbociclib) combination therapy is a new option. The safety and efficacy of palbociclib have been evaluated in Phase II PALOMA-1 and Phase III PALOMA-2 and PA The LOMA-3 clinical study demonstrated that the combination of letrozole or fulvestrant significantly improved median progression-free survival (PFS) compared with letrozole alone or placebo plus letrozole or placebo plus fulvestrant. The 5-year long-term analysis showed that palbociclib combined with endocrine therapy has a consistent and stable safety profile without cumulative or delayed toxicity.